Polatuzumab Vedotin: Late Stage Clinical Development to Approval

Time: 9:30 am
day: day 2- am


  • Providing an overview of the late stage clinical development of polatuzumab vedotin
  • Discussing rational combination strategy in R/R DLBCL leading to approval of polatuzumab vedotin + BR
  • Sharing the rational combination strategy in 1L DLBCL leading to positive results of the Phase III POLARIX with polatuzumab vedotin + R-CHP